Acute respiratory distress in adults. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Lancet 1967; 2(7511): 319-323. The American-European Consensus Conference on ARDS: definitions, mechanism, relevant outcomes and clinical coordination. Am J Respir Crit Care Med 1994;149:818-24. The ARDS Definition Task Force. Acute Respiratory Distress Syndrome: The Berlin Definition. JAMA 2012;23:2526-33. Acute respiratory distress syndrome definition: do we need a change? Villar J, Blanco J, Kacmarek RM. Curr Opin Crit Care 2011; 17(1): 13-17. Luhr OR, Antonsen K, Karlsson M, Aardal S, Thorsteinsson A, Frostell CG, et al. Incidence and mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden, Denmark, and Iceland. The ARF Study Group. Am J Respir Crit Care Med. 1999;159:1849-61. Estenssoro E, Dubin A, Laffaire E, Canales H, Sáenz G, Moseinco M, et al. Incidence, clinical course, and outcome in 217 patients with acute respiratory distress syndrome. Crit Care Med. 2002;30:2450-6. Esteban A, Anzuelo A, Frutos F, Alia I, Brochard L, Stewart TE, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA. 2002;287:345-55. Roupie E, Lepage E, Wysoki M, Fagon JY, Chastre J, Dreyfuss D, et al. Prevalence, etiologies and outcome of acute respiratory distress syndrome among hypoxemic ventilated patients. SRLF Collaborative Group on Mechanical Ventilation. Societé de Reanimation de Langue Française. Intensive Care Med. 1999;25:920-9. Moss M, Mannino DM. Race and gender differencies in acute respiratory distress syndrome deaths in the United States: An analysis of multiple-cause mortality data (1979-1996). Crit Care Med. 2002;30:1679-85. The Acute Respiratory Distress Syndrome Network. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med. 2004;351: 327-36. Zileberberg MO, Epstein SK. Acute lung injury in the medical ICU: comorbid conditions, age, etiology, and hospital outcome. Am J Respir Crit Care Med. 1998;157:1159-64. Brun-Buisson C, Minelli C, Bertolini G, Brazzi L, Pimentel J, Lewandowski K, et al. Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study. Intensive Care Med. 2004;30:51-61. Wright JR. Immunomodulatory functions of surfactant. Physiol Rev 1997;77: 931-62. Blanco O. Propiedades antiinflamatorias del surfactante pulmonar y su aplicación en la clínica. Biotecnología Aplicada 2004;21:70-6. Navas VM, Cuevas MA, Vila JA, Martínez V, Morcillo V, Valls A. Profilaxis y tratamiento del síndrome de distress rexpiratorio con diferentes surfactantes. Anales de Pediatría, 2002; Número 01, Volumen 56 p. 40-44; Ediciones Doyma, SL. http://www.doyma.es Creuwels LAJM, Van Golde LMG, Haagsman HP. The pulmonary surfactant system: biochemical and clinical aspects (Review). Lung 1997;175:1-39. Fernández -Regalado R, Manzanares D y Veldhuizen R. Aspectos biofísicos en la evaluación del surfactante natural Surfacen. Rev Cub Invest Biomed Jul-Dic 1993; 12(2): 93-99. Manzanares D, Escobar A, Colomé H, Noa M, Fernández Regalado R, Alfonso W, Muñoz MC, Alfonso HA, García L y Moreno O. Surfactante pulmonar de origen porcino para uso terapéutico. Rev Salud Animal 1994; 16: 51-58. Centro Nacional de Sanidad Agropecuaria. Expediente de Registro SURFACEN, 1995-1996. Centro Nacional de Sanidad Agropecuaria. Expediente de la Renovación SURFACEN, 2001. Centro Nacional de Sanidad Agropecuaria. Expediente de la Modificación SURFACEN, 2002. Centro Nacional de Sanidad Agropecuaria. Expediente de Modificación CECMED SURFACEN, 2003. Blanco O, Riverón Y, de Armas E, Sánchez J, Faure R, Fernández O. SURFACEN® inhibe el crecimiento de bacterias causantes de infecciones respiratorias. Biotecnología Aplicada 2005;22:279-81. Neumeister B, Woerndle S, Bartmann P. Effects of different surfactant preparations on bacterial growth in vitro. Biol Neonate 1996;70:128-34. Rauprich P, Möller O, Walter G, Herting E, Robertson B. Influence of modified natural or synthetic surfactant preparations on growth of bacteria causing infections in the neonatal period. Clinical and Diagnostic Laboratory Immunology 2000;7:817-22. Bouhafs RK, Jarstrand C. Lipid peroxidation of lung surfactant by bacteria. Lung 1999;177:101-10. Blanco 0, Beltrán A, González D, Sánchez J, Fernández 0, Faure R, Delgado R. Propiedades biofísicas, anti-inflamatorias y antibacterianas de SURFACEN® y su protección del daño oxidativo por la SP-A. Tesis de doctorado. 2006. Sola A y Rogido M. Cuidados especiales del feto y el recién nacido. Editorial Científica Interamericana. Argentina. 2001: 1254-1300. Lang MJ, Hall R, Reddy NS, Krurth CG, Merritt TA, A controlled trial of human surfactant replacement therapy for severe respiratory distress syndrome in very low birth weight infants. J Pediatr 1990; 116: 295-300 Lachmann B, van Golde LMG, eds. 60 Years of Sufactant Reserch. Final Programms and abstracts. Floating Congress on the River Rhine. 1989; (Abstracts): 11-17. Couser RJ, Ferrara TB, Ebert J, Hoekstra RE, Fangman JJ, Effects of exogenous surfactant therapy on dynamic compliance during mechanical breathing in preterm infants with hyaline membrane disease. J Pediatr 1990; 116: 119-24. Manzanares D, Fernández R, Moreno O, Torres O, Colomé H. SURFACEN: Un surfactante natural para el tratamiento del síndrome del distress rexpiratorio neonatal. Revista Cubana de Pediatría 1997; 69(1): 3-10. Acosta R, Arronte J, Cabrera N. Evaluación del SURFACEN en el síndrome de dificultad respiratoria del prematuro. Revista Cubana de Pediatría 2000; 72 (4): 287-9. Wright JR. Pulmonary surfactant: a front line of lung host defense. J Clin Invest 2003; 111: 1453-1455. Spragg RG, Lewis JF. Surfactant therapy in the acute respiratory distress syndrome. In: Matthay MA, ed. Acute respiratory distress syndrome. New Cork: Marcel Dekker, 2003: 533-62 Kesecioglu J, Schultz MJ, Lundberg D, Lauven PM, Lachmann B. Treatment of acute luna injury (ALI/ARDS) with surfactant. Am J Respir Crit care Med 2001; 165: A819-A819. abstract. Ware LB, Matthay MA, The acute respiratory distress síndrome. N Engl J Med 2000; 342: 1334-1349. McIntyre RC Jr, Pulido EJ, Bensard DD, Shames BD, Abraham E. Thirty years of clinical trials in acute respiratory distress síndrome. Crit Care Med 2000; 28: 3314-3331. The Acute respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342: 1301-1308. Da Costa DE, Pai MGK, Al Khusaiby SM. Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiencies in a developing country. Pediatr Pulmonol 1999; 27: 312-317. Malathi I. Differences in immediate and short-term outcome of premature neonates treated with two types of exogenous surfactant preparation. Ann Acod Med Singapore, 1995; 24: 781-784. Kresch MJ, Clive JM. Meta-analyses of surfactant replacement therapy of infants with birth weights less than 2000 grams. J Perinatol 1998; 18: 276-83. Hudak ML, Farrell EE, Rosenberg AA, Jung AL, Auten RL, Durand DJ et al. A multicenter randomized, masked comparation trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr 1996; 128: 396-406. Martín I, Fernández R y Rodríguez A. SPA, proteína del surfactante pulmonar en función del diagnóstico y del tratamiento. Rev Cuba Invest Biomed Jul-Dic 1991; 10(2):81-86. Halladay HI. Surfactants: Past, present and future. J. Perinatology. 2008. 28: S47-S56. Speer CP, Gefeller O, Groneck P, Laufkötter E, Roll C, Hanssler L et al. Randomized clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child 1995; 72: F8-F13. Marco A, Marco A, Martínez JM, Beltrán JJ, Rebaje V, Rite S et al. Tratamiento del SDRA con diferentes tipos de surfactante exógeno, estudio comparativo. An Esp Pediatr 1995; 73: 146. Nohara K, Berggren P, Curstedt T, Grossman G, Nilsson R, Robertson B. Correlations between physical and physiological properties of various preparations of lung surfactant. Eur J Respir Dis 1986; 69: 321-335. [Medline] Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K, A randomized, multicenter masked comparison trial of poractan alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Nor American Study Group. Am j Perinatol. 2004 Apr, 21 (3): 109-19. Spragg RG, Gilliard N, Richman P, et al. Acute effects of a single dose of porcine surfactants on patients with the adult respiratory distress syndrome. Chest 1994; 105: 195-202. Gregory TJ, Steinberg KP, Spragg RG, et el. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit care Med 1997; 155: 1309-1315. Spragg RG, Smith RM, Harris K, lewis j, Hafner D, Germann P. Effect of recombinant SP-C surfactant in a porcine lavage model of acute lung injury. J Appl Physiol 2000; 88: 674-681. Spragg RG, Lewis JF, Wurst W, et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J respire Crit Care Med 2003; 167: 1562-1566. Spragg RG, Lewis JF, Hans-Dieter W, et al. Effect of Recombinant Surfactant Protein C-Based Surfactant on the Acute Respiratory Distress Syndrome. The New England Journal Medicine 2004; 351 (9): 884-892. Moreno V, O; Lee L, M; Domínguez D, F et al. Estudio de la eficacia del SURFACEN en el distress respiratorio del recién nacido. Rev. Cubana Pediatr, Apr-June 1999, vol.71,  2, p.60-71. ISSN 0034-7531. Manzanares D; Fernández R; Moreno O; Torres O; Colomé H; SURFACEN: Un surfactante natural para el tratamiento del síndrome del distress respiratorio neonatal. Rev Cubana Pediatr 1997; 69 (1): 3-10. Acosta R; Arronte J; Cabrera N. Evaluación del SURFACEN en el síndrome de dificultad respiratoria del prematuro. Rev Cubana Pediatr 2000; 72 (4): 287-94. Morilla A, Yera IB, Díaz E, Fernández O, Martín AI y col. Informe de resultados del procesamiento del estudio postcomercialización de SURFACEN®. 2007-2009. Sánchez M, Martínez OC, Herrera N, Ortega J. Estudio controlado del tratamiento de la enfermedad de membrana hialina del recién nacido pretérmino con surfactante pulmonar exógeno (porcino vs. bovino). Gac Méd Méx Vol. 141 No. 4, 2005. Rybert F.; Lee M.; Correa F. y Navarrete G. Informe final de la investigación en fase IV del ensayo clinico del producto surfacen en Chile. Informe final de ensayo clínico. Chile: Unidad de neonatología del Hospital Barros Luco- Trudeaux, Ministerio de Salud de Chile. 12p. 1996 Marinelli WA, Ingbar DH.: Diagnosis and management of acute lung injury. Clin Chest Med 1994; 15(3):517-46. Tomashefski, JF. Pulmonary pathology of the adult respiratory distress syndrome. Clin Chest Med 1990; 11:593 Correa H, Baraibas J. Neumonía asociada a ventilación artificial. CTI Universitario 25 años. De. Dos Puntos. Montevideo; 1996:176-90. Olivera WG, Sznajder IJ. Biología del agua pulmonar en los pacientes críticos. CTI Universitario 25 años. Dos Puntos, Montevideo; 1996:93-112. Andersen JB. Improving ventilatory strategy. Fourth De. Intensive Care Unit 542, Hvidovre, Copenhagen: Hospital Copenhagen University Medical School; 1992:36-44. Santos C. Insuficiencia respiratoria aguda en la enfermedad obstructiva crónica. CTI Universitario 25 años. De. Dos Puntos. Montevideo; 1996:113-33. Márquez C, et al. Insuficiencia respiratoria aguda. Manual de diagnóstico y terapéutica médica 2da. ed Dpto. Medicina Int. Hospital 12 Octubre, Universidad Complutense de Madrid. Madrid; l990:241-52. Barie PS. Organ-specific support in multiple organ failure: pulmonary support. World J Surg; 1995; 19:581-91. Weg JG, Balk RA, Tharratt RS, Jenkinson SG, Shah JB, Zaccardelli D, Horton J, Pattishall EN: Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA 1994, 272:1433-1438. Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventos AA, Lemaire F, Long W, Zaccardelli D, Pattishall en: Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl J Med 1996, 334:1417-1421. Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore WJ, Moxley MA, Cai GZ, Hite RD, Smith RM, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997, 155:1309-1315. Spragg RG, Lewis JF, Wurst W, Hafner D, Baughman RP, Wewers MD, Marsh JJ. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 2003, 167:1562-1566. Spragg RG, Lewis JF, Walmrath D, Johannigman J, Bellingan G, Laterre PF, Witte MC, Richards GA, Rippin G, Rathgeb F, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 2004, 351:884-892. Davison WJ, Dorscheid D, Spragg R, Schulzer M, Mak E, Ayas N. Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome. Results of a meta-analysis. Critical Care 2006, 10(2):R41. Meng H, Sun Y, Lu J, Fu S, Meng Z, Scott M, Li Q. Exogenous surfactant may improve oxygenation but not mortality in adult patients with acute lung injury/acute respiratory distress syndrome: a meta-analysis of 9 clinical trials. J Cardiothorac Vasc Anesth, 2012 Oct;26(5):849-56. Hidalgo OA, Barrese Y, Díaz E, Uranga R, Fernández O, Avila Y y col. Informe final del ensayo clínico fase II “Evaluación de la eficacia y la seguridad del SURFACEN en el tratamiento del Síndrome de Distress Respiratorio Agudo en el Adulto”. Mayo del 2011. Sánchez C; Torres J. Surfactante pulmonar. Rev. Ped. Elec. 2004, Vol 1,  1. ISNN 0718-0918. Díaz E. SURFACEN surfactante natural. Manual de Consulta. CENSA. 2008 Kobayashi T, Shido A, Nitt K, Inou S, Ganzuka M, Robertson B. The critical concentration of surfactant in fetal lung liquid at birth. Respiration Physiology 1990;80:181-92. Hallman M, Merrit TA, Kari A, Bry K. Factors affecting surfactant responsiveness. Annals of medicine 1991;23:693-8. Strayer DS, Merrit TA, Hallman M. Surfactant replacement: inmunogenical considerations. Eur respire J 1989; 2, Suppl 3, 91-6. Díaz H, Manzanares D, Sosa A, Hidalgo O, Pastrana I, Díaz A et al. Low Doses of Surfactant in the Treatment of Adult Respiratory Distress Syndrome. Hospital Docente Universitario “Calixto García”. 1er Congreso de Medicina Crítica en Internet 17-24 Noviembre, 1999. http://www.uninet.edu/cimc99/abstract/00130AO.html